NEURAMIS

Pharmaceuticals, namely, hyaluronate acid and modified hyaluronate acid for use as a soft tissue filler for treatment of damaged tissue; specialized medical capsules, namely, self-contained ampules sold filled with pharmaceuticals for use in dispensing the same in the nature of prepackaged hyaluronic acid and derivatives thereof alone, and in combination with other polysaccharide for pharmaceutical purposes in particular starch, cellulose esters, and with and without lidocaine; dermal tissue filler kits comprising hyaluronic acid gel sold in pre-filled syringes for injecting under the skin for use in reducing and eliminating fine skin lines and wrinkles, filling scars, and contouring the lips and face; pharmaceutical preparations, namely, hyaluronic acid and modified hyaluronic acid, and its derivatives and salts, and biological skin tissue for implantation, all sold in pre-filled syringes for eliminating fine skin lines and wrinkles

Dermatological implants for medical use consisting of artificial materials in the nature of visco-supplementation substances for filling skin wrinkles and increasing skin volume